Hilarious Twitter Updates And Messages Regarding AP24534

05 level were entered into multivariate logistic regression models for BRAF positivity. To remove redundancy and improve the predictive value of the multivariate analysis, complex variables such as AJCC Stage were reduced to the variables they comprise, such as histologic tumor size, extrathyroidal extension, and location of disease at diagnosis. Kaplan�CMeier analysis was also performed to estimate the recurrence-free survival and DSS probabilities for BRAF mutation positive versus negative patient groups. Statistical analyses were performed using SAS, Version 9.2 (SAS Institute, Inc., Cary, NC). Results Patient characteristics A total of 508 patients meeting eligibility criteria with evaluable tissue underwent BRAF gene analysis. Patient and tumor characteristics are illustrated in Table?Table1.1. Average age at diagnosis was 45.5?��?15.1?years (range 5.8�C84.6?years, median UNC2881 45.1?years) and mean follow-up time was 9.8?years with a median follow-up time of 8.0?years (range of 0.1�C40.1?years). Pathological findings Angiogenesis inhibitor included thyroid capsular invasion in 47%, vascular invasion in 15%, microscopic positive margins in 28%, soft tissue invasion in 30%, and bilateral thyroid involvement in 36%. The average histologic tumor size was 2.0?��?1.7?cm at the largest dimension. The majority of patients had disease limited to the thyroid only (54.8%, 278/507), 42.2% had disease in the neck nodes and thyroid, 2.8% had distant metastases to the lung, and 0.2% had disease in the thyroid and bone metastases. Table 1 Patient, tumor and treatment characteristics stratified by BRAFV600 mutation BRAF analysis The BRAF mutation was present in 66.9% of patients (340/508). Mutation status was identified by RFLP, which displayed two, wild-type DNA STI571 price bands (120 and 95?bp) digested by the TspRI restriction enzyme when the BRAF V600 mutation was absent, and three DNA bands (215, 120, and 95?bp) when the BRAF V600 mutation was present (heterozygote). Representative cases are illustrated in Figure?Figure1.1. Follow-up time did not differ between BRAF-positive and BRAF-negative patients (P?=?0.507). Initial RAI dose also did not differ between BRAF-positive and -negative patients (P?=?0.824). The presence of the BRAF mutation was associated with classic papillary histology (P?=?0.003), capsular invasion (P?=?0.001), soft tissue invasion (P?